Search Results - "Horie, Yoshiki"

Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study by Nakamura, Michio, Ishiguro, Atsushi, Dazai, Masayoshi, Kawamoto, Yasuyuki, Yuki, Satoshi, Sogabe, Susumu, Hosokawa, Ayumu, Sawada, Kentaro, Muto, Osamu, Izawa, Naoki, Nakashima, Koji, Horie, Yoshiki, Yagisawa, Masataka, Kajiura, Shinya, Ando, Takayuki, Mitsuhashi, Yosuke, Sunakawa, Yu, Kikuchi, Yasuka, Komatsu, Yoshito

“…Although initial therapy with a parenteral anticoagulant is required before edoxaban, this strategy is frequently avoided in actual clinical practice because…”
Get full text

Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer by Doi, Ayako, Mizukami, Takuro, Takeda, Hiroyuki, Umemoto, Kumiko, Arai, Hiroyuki, Horie, Yoshiki, Izawa, Naoki, Ogura, Takashi, Sunakawa, Yu

“…Geriatric 8 (G8) and instrumental activities of daily living (IADL) are recommended to predict overall survival (OS) or risk of serious adverse events (SAEs)…”
Get full text

Phase Ib study of FOLFOXIRI plus ramucirumab as first-line treatment for patients with metastatic colorectal cancer by Kito, Yosuke, Satake, Hironaga, Taniguchi, Hiroya, Yamada, Takeshi, Horie, Yoshiki, Esaki, Taito, Denda, Tadamichi, Yasui, Hisateru, Izawa, Naoki, Masuishi, Toshiki, Moriwaki, Toshikazu, Mori, Keita, Yamazaki, Kentaro

“…Purpose Ramucirumab, an anti-vascular endothelial growth factor (VEGF) receptor2 monoclonal antibody, inhibits VEGF-A, VEGF-C, and VEGF-D binding and…”
Get full text

Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy by Taniyama, Tomoko Katsui, Tsuda, Takashi, Miyakawa, Kunihisa, Arai, Hiroyuki, Doi, Ayako, Hirakawa, Mami, Horie, Yoshiki, Mizukami, Takuro, Izawa, Naoki, Ogura, Takashi, Sunakawa, Yu, Nakajima, Takako Eguchi

“…Background and aim Fistula is one of the known complications of T4 esophageal cancer (T4-EC). The standard treatment for T4-EC is chemoradiotherapy, but…”
Get full text

Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis by Kaira, Kyoichi, Horie, Yoshiki, Ayabe, Eriko, Murakami, Haruyasu, Takahashi, Toshiaki, Tsuya, Asuka, Nakamura, Yukiko, Naito, Tateaki, Endo, Masahiro, Kondo, Haruhiko, Nakajima, Takashi, Yamamoto, Nobuyuki

“…Pulmonary pleomorphic carcinoma is a rare epithelial tumor and has an aggressive clinical course. As few studies of pulmonary pleomorphic carcinoma have been…”
Get more information

Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers by Takeda, Hiroyuki, Imoto, Kiyomi, Umemoto, Kumiko, Doi, Ayako, Arai, Hiroyuki, Horie, Yoshiki, Mizukami, Takuro, Oguri, Tomoyo, Ogura, Takashi, Izawa, Naoki, Yamamoto, Hiroyuki, Yamano, Yoshihisa, Sunakawa, Yu

“…Background Comprehensive analyses of cancer-related genomic alterations are expected to lead to increased availability of targeted therapies. However, in…”
Get full text

Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer by Nakajima, Takako Eguchi, Boku, Narikazu, Doi, Ayako, Arai, Hiroyuki, Mizukami, Takuro, Horie, Yoshiki, Izawa, Naoki, Hirakawa, Mami, Ogura, Takashi, Tsuda, Takashi, Sunakawa, Yu

“…Summary KRAS wild-type colorectal cancers initially responsive to anti-endothelial growth factor receptor (EGFR) antibodies [cetuximab (Cetu)/panitumumab…”
Get full text

Rationale and design of a multicenter, double-blinded, randomized, placebo-controlled trial to investigate the effects of naldemedine on opioid-induced constipation for patients with cancer pain: A study protocol by Higashibata, Takahiro, Hamano, Jun, Kessoku, Takaomi, Kajiura, Shinya, Hirakawa, Mami, Horie, Yoshiki, Shimizu, Masaki, Oyamada, Shunsuke, Ariyoshi, Keisuke, Kihara, Kota, Yamanaka, Yohei, Konishi, Kumi, Doki, Kosuke, Takashima, Yasuyuki, Horiuchi, Manabu, Homma, Masato, Yamada, Takeshi, Yamamoto, Yoshiyuki, Moriwaki, Toshikazu, Morita, Tatsuya, Nakajima, Atsushi, Nagaoka, Hiroka

“…It is unclear which laxatives are appropriate to prevent opioid-induced constipation (OIC). This study will evaluate whether prophylactic use of naldemedine…”
Get full text

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib by Arai, Hiroyuki, Miyakawa, Kunihisa, Denda, Tadamichi, Mizukami, Takuro, Horie, Yoshiki, Izawa, Naoki, Hirakawa, Mami, Ogura, Takashi, Tsuda, Takashi, Sunakawa, Yu, Nakajima, Takako Eguchi

“…It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present…”
Get full text

A guideline for antimetics use for patients with malignancies by Horie, Yoshiki, Boku, Narikazu

“…Although recent advances in chemotherapy have led to improvement of QOL and prolonged survival for patients with advanced cancer, we often cannot continue…”
Get more information

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study) by Makiyama, Akitaka, Sukawa, Yasutaka, Kashiwada, Tomomi, Kawada, Junji, Hosokawa, Ayumu, Horie, Yoshiki, Tsuji, Akihito, Moriwaki, Toshikazu, Tanioka, Hiroaki, Shinozaki, Katsunori, Uchino, Keita, Yasui, Hirofumi, Tsukuda, Hiroshi, Nishikawa, Kazuhiro, Ishida, Hiroyasu, Yamanaka, Takeharu, Yamazaki, Kentaro, Hironaka, Shuichi, Esaki, Taito, Boku, Narikazu, Hyodo, Ichinosuke, Muro, Kei

“…This study evaluated the continuous use of trastuzumab beyond progression (TBP) in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric or…”
Get full text

MO18-6 Predictive value of CDC37 gene expression for regorafenib in metastatic colorectal cancer (mCRC) by Arai, Hiroyuki, Denda, Tadamichi, Kubota, Yohei, Takeda, Hiroyuki, Doi, Ayako, Horie, Yoshiki, Umemoto, Kumiko, Izawa, Naoki, Sunakawa, Yu

Get full text

MO35-2 Symptom monitoring and its digitalization at daily cancer chemotherapy in Japan: a nation-wide multi-stakeholder survey by Horie, Yoshiki, Miyaji, Tempei, Kawaguchi, Takashi, Kaneyasu, Takako, Nagashima, Fumio, Doi, Ayako, Uneno, Yu, Ogura, Takashi, Yamaguchi, Takuhiro, Nakajima, Takako

Get full text

The Molecular Landscape of Pancreatobiliary Cancers for Novel Targeted Therapies From Real-World Genomic Profiling by Umemoto, Kumiko, Yamamoto, Hiroyuki, Oikawa, Ritsuko, Takeda, Hiroyuki, Doi, Ayako, Horie, Yoshiki, Arai, Hiroyuki, Ogura, Takashi, Mizukami, Takuro, Izawa, Naoki, Moore, Jay A, Sokol, Ethan S, Sunakawa, Yu

“…Abstract Background Chemotherapies have limited efficacy in pancreatic cancer (PC) and biliary tract cancer (BTC), underscoring the need for new regimens…”
Get full text

Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study by Ikeda, Masafumi, Nomura, Shogo, Kobayashi, Tatsushi, Kimura, Yasutoshi, Morinaga, Soichiro, Toyama, Hirochika, Sugiura, Teiichi, Hirano, Satoshi, Shimizu, Yasuhiro, Tomikawa, Moriaki, Sadamori, Hiroshi, Katanuma, Akio, Horie, Yoshiki, Unno, Michiaki, Sugimachi, Keishi, Yamaguchi, Hironori, Kojima, Motohiro, Akimoto, Tetsuo, Uesaka, Katsuhiko, Takahashi, Shinichiro

“…LBA4014 Background: No randomized controlled trials have compared systemic chemotherapy and chemoradiotherapy as neoadjuvant therapy for borderline resectable…”
Get full text

MO1-2 Geriatric assessment and clinical outcomes for elderly colorectal cancer patients by Doi, Ayako, Takeda, Hiroyuki, Umemoto, Kumiko, Arai, Hiroyuki, Horie, Yoshiki, Mizukami, Takuro, Izawa, Naoki, Ogura, Takashi, Oguri, Tomoyo, Sunakawa, Yu

Get full text

P31-7 Clinical outcomes of cerebral infarction associated with Trousseau’s syndrome in advanced pancreatic cancer patients by Oguri, Tomoyo, Takeda, Hiroyuki, Umemoto, Kumiko, Doi, Ayako, Arai, Hiroyuki, Horie, Yoshiki, Mizukami, Takuro, Izawa, Naoki, Ogura, Takashi, Sunakawa, Yu

Get full text

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors by Shimizu, Toshio, Nakajima, Takako Eguchi, Yamamoto, Noboru, Yonemori, Kan, Koyama, Takafumi, Kondo, Shunsuke, Sunakawa, Yu, Izawa, Naoki, Horie, Yoshiki, Xiang, Silong, Xu, Siying, Qin, Lan, Gong, John, Liu, David

“…Envafolimab is the first and only globally approved subcutaneously injectable PD-L1 antibody. This open-label, multicenter Phase 1 trial assessed the safety,…”
Get full text

MO19-3 Subgroup analyses of phase II study of weekly paclitaxel in advanced esophageal cancer that had previously received docetaxel-containing chemotherapy by Nakashima, Koji, Ando, Takayuki, Yoshida, Hiroki, Sakumura, Miho, Nomura, Motoo, Muto, Manabu, Fujii, Hirofumi, Horie, Yoshiki, Takeda, Hiroyuki, Yoshii, Takako, Tahara, Yoshihiro, Katada, Chikatoshi, Yoshimura, Kenichi, Hideki, Ishikawa, Hosokawa, Ayumu

Get full text

Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing by Takeda, Hiroyuki, Yamamoto, Hiroyuki, Oikawa, Ritsuko, Umemoto, Kumiko, Doi, Ayako, Horie, Yoshiki, Mizukami, Takuro, Ogura, Takashi, Izawa, Naoki, Moore, Jay A., Sokol, Ethan, Sunakawa, Yu

“…Abstract only 642 Background: Panel-based comprehensive genomic profiling (CGP) is used in clinical practice worldwide, however, large aggregated RWD of…”
Get full text